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Introduction
When treatment plan comparisons are performed in the clinic, the planner normally presents the dose distributions in all CT-slices together with dosevolume histograms (DVHs) and relevant dose-volume metrics for the radiation oncologists (ROs). The ROs use not only these data but also their clinical experience to thoroughly evaluate the differences between plans, in order to choose, in their opinion, the one most clinically beneficial for the patient. The ROs' review primarily addresses treatment quality aspects but it may also take into account treatment resource allocation. If this form of plan comparison is quantified it becomes a type of clinical grading of a treatment plan. Visual grading of the reproduction of important anatomical structures has become a well established method to determine image quality within the field of radiology [1] . In this study we use a similar analysis method as the one used in radiology for visual grading (visual grading analysis, VGA) to benefit from the clinical assessment by ROs for the comparison of treatment plans. Hence, we call the method clinical grading analysis (CGA). Published studies on treatment plan comparisons often involve quantitative comparisons of physical measures, e.g. DVH parameters, dose-volume statistics [2] [3] [4] [5] [6] , and sometimes parameters derived from biological models, e.g. normal tissue complication probability (NTCP), tumor control probability (TCP) or equivalent uniform dose (EUD) [7] . Such comparisons may show a numerical advantage for one plan (or treatment technique) over another, but the clinical relevance of the results may not be as clear. Furthermore, by only reviewing such parameters important treatment plan details might be overlooked, e.g. hot-spots, cold-spots, or the extension of the "dose bath" volume, details only clearly visible in the 3D-dose distributions. As dose distributions inspections are included in the CGA and as it also involves clinical judgments, it could potentially offer information other than what is acquirable from published studies based solely on dose-volume metrics.
In this study we use CGA to compare treatment plans generated for the different advanced treatment techniques available at our clinic, i.e. helical tomotherapy (HTT) and step-and-shoot intensity-modulated radiation therapy (SS-IMRT).
Results from the CGA are compared with dose-volume statistics and EUD-data.
The purpose was to see if CGA could be useful for treatment plan comparisons and how it correlates with the dosimetric evaluation parameters mentioned above.
With CGA, the quality of the investigated treatment plans are not assessed or compared in an absolute sense. Rather, the idea with the method is to identify clinically relevant differences between the plans. These are assumed to be revealed by analyzing the grading scores, resulting from the clinical assessments performed by the ROs. The systematic use of clinical grading could provide a support for treatment technique decisions and help optimize the use of a clinic's advanced treatment resources. It would also ensure that a clinical judgment is included in treatment plan comparisons.
Materials and Methods
Twenty-three HTT plans, originally made for patients treated at our tomotherapy unit (TomoTherapy Incorporated, WI, USA) were randomly selected for this study. Five brain tumor cases, five head and neck (H&N) cancers, eight cases with intrathoracic tumors, two cases with tumors in the abdominal region, and three in the pelvic region were chosen (see Appendix). A seven-beam SS-IMRT plan was generated for each of these patient cases with the use of SharePlan TM software, a back-up system for HTT plans. Previous studies have shown that plans generated in SharePlan are deliverable and comparable to plans generated by conventional SS-IMRT planning [8, 9] . All cases had originally been considered by the ROs to be in need of treatment with an advanced treatment technique, although being of varying complexity. It could be expected that for the more complex cases HTT should be the superior technique while for less complex cases there might be no significant difference between HTT and the SS-IMRT plans [8] . given if the SS-IMRT plan was judged as considerably better than the HTT plan, "B" as somewhat better, "C" as equivalent, "D" as somewhat worse, and "E" as considerably worse. The ROs were also asked to motivate their judgment.
One-sided sign tests [10] were performed to test the statistical significance of the clinical grading results from the plan comparison. The tests were performed on the results for all cases separately, for all ROs separately, as well as for all results combined. The significance level chosen was 5% (α=0.05).
The following dose-volume statistics for the plans were taken from the Oncentra treatment planning system; dose coverage for the clinical target volume (CTV) and the planning target volume (PTV) as well as the mean doses for all organs at risk (OARs). The mean doses to the OARs for each of the cases were condensed to a single value by calculating the average mean dose value for an OAR (AMD OAR ). This value is not correlated with a clinical end-point but can still be useful for treatment plan comparisons, especially when comparing plans that are very similar and given that all hard dose constraints are fulfilled. This methodology was inspired by the remaining volume at risk (RVR) concept presented in ICRU 83 [11] . DVHs for the plans were exported from Oncentra to MS Excel where generalized EUD [12] data were calculated for all OARs and targets, according to:
where D i and v i are the dose in bin i and its differential fractional volume, respectively, and a is a tissue-specific parameter describing the volume dependence of the organ [13] . The a-values used for these calculations for the OARs were taken from the QUANTEC report [14] and references therein. The avalue for tumor tissue was set to -10, for all target structures. An EUD-based index proposed by Semenenko et al. [13] as an overall quantitative measure of dosimetric and biological plan effectiveness, was calculated for each plan according to: All plans were generated in a way that all clinical dose constraints for the critical (dose limiting) OARs were fulfilled, i.e. the maximum doses to the critical OARs were kept below the dose levels associated with a risk for (unwanted) serious side effects. Hence, the dose limiting OARs were not specifically considered by the ROs during the clinical grading, and the maximum doses to these are therefore not presented in the results.
Results
The results from the CGA are presented in Table 1 Dose-volume statistics and corresponding EUD-data for the different plans are displayed in Table 2 . These results reveal that a difference in CTV coverage of 1.3 % or more (≥ 0.5 Gy difference in EUD-data) correlates with a significant CGA result, i.e. for these cases the ROs agreed that there was a clinical advantage for the plan with the superior dose coverage (cases H 1, and P 1). Cases with similar CTV coverage, but with a difference in PTV coverage of 2.2 % or more, also had a significant result in the CGA (cases B 3, I 4, and I 6). However, there was not a clear specific difference in PTV EUD-value correlating with a significant result in the CGA (0.6, 0.1, and 0.2 Gy for cases B 3, I 4, and I 6, respectively). Cases where the SS-IMRT plan had similar or somewhat superior (0.3 %) CTV and PTV coverage than the HTT plan, and also had a lower average mean dose value for an OAR (AMD OAR ) of at least 2.5 Gy, corresponded to a significant result in the CGA (cases I 7, and I 8). For cases where the plans had similar AMD OAR but one plan had a somewhat worse target coverage, the ROs disagreed on whether the differences in target coverage were of clinical importance or if the plans were equivalent. This was indicated in the results from the CGA (Table 1) as one plan seemed to be somewhat superior but the superiority was too unclear to give a significant result (cases H 4, I 3, I 5, A 1, P 2, and P 3). For cases where one plan had a somewhat worse target coverage but also had a lower AMD OAR value, the ROs disagreed on whether one or the other plan was the superior one, or if the differences cancelled out making the plans equivalent (cases B 4, H 3, I 1, and A 2).
Discussion
In studies comparing plans generated with different IMRT treatment delivery techniques, the clinical relevance for the differences found is often unclear [4] . In this study we try to mitigate this issue by using CGA as a tool for treatment plan The results from the CGA correlated well with differences in target coverage and doses to OARs (presented under dose-volume statistics in Table 2 ). However, the correlation was weaker between the results from the CGA and EUD-data. The better correlation between CGA and dose-volume statistics than between CGA and EUD-data is likely due to the fact that the dose-volume statistics parameters are directly visible in the DVHs. These were, as mentioned earlier, among the data presented to the ROs during the clinical grading while EUD-data was not. The The cranio-caudal penumbra effect for tomotherapy treatments was the main reason why some of the HTT plans were considered significantly inferior to the SS-IMRT plans, similar to results found in other studies [2, 15] . In order to reduce this unwanted effect, a dynamic jaw is under development by the vendor, which has the potential to essentially remove the penumbra effect [15] . The other drawback found was for cases where the rotating beam was limited by OARs to only a few and small angle intervals. This resulted in poor treatment plans for helical delivery mode, which has also been reported in previous studies [2, 16] .
Such cases should not be prioritized for treatment with the tomotherapy system, since treatments delivered by SS-IMRT are comparable or better.
This study was not blind, i.e. the ROs were told which plan was generated for HTT, and which was generated for SS-IMRT treatment delivery, since this was obvious merely by observing the dose distributions for the various treatment techniques. In order to ensure that all participants had the same background information, everyone was informed about the treatment modalities. This knowledge could possibly have biased the results, if the participants preferred some treatment technique, and it might have influenced their grading score. For cases where the OAR dose constraints were all fulfilled, the differences in judgment seen between the participating ROs could be due to subjective preferences, differences in educational background, or due to the lack of specific treatment objectives in the clinic [17] . By performing a CGA these differences are revealed which can be a first step towards developing a more congruent judgment within the clinic.
This study presents CGA as a useful method of comparing radiotherapy treatment plans. Another useful method for comparing treatment plans is the Pareto evaluation concept, which has some advantages compared to conventional DVHbased methods [8, [17] [18] [19] . A CGA study would serve as a good complement to a Pareto evaluation study since it takes advantage of the ROs clinical assessment to identify the clinical relevant differences between treatment plans. These subjective assessments are quantified in this CGA study, and used to decide which patients that had a clinical benefit of one or the other of the advanced treatment techniques available to them, i.e. HTT and SS-IMRT. The result from the study provides a support for decision making on treatment technique at our clinic with a limited number of treatment slots available for HTT and SS-IMRT treatment, which ensures a more optimal use of our advanced treatment resources.
Information from published studies regarding choice of treatment technique might not be applicable for every clinic, as they rarely involve clinical judgments and do not take into account characteristics of a specific clinic, e.g. resources available.
Hence, a CGA can help to decide how to best implement the treatment technique, locally. In summary, the proposed method for comparing treatment techniques offers a formalized way of introducing and evaluating the implementation of new radiotherapy techniques in a clinical setting. 
